FDA's Shift on Hormones: Removing Warnings and Misclassifications
PILLAR DIAGNOSTIC // WEEK 12
“The analysis indicates a predominantly positive outlook regarding hormonal treatments and their effects, particularly in the context of menopausal women. The risk stemming from the mood pillar reflects a broader political concern rather than a direct health-related risk. Consequently, the resolution of divergence rests on distinguishing between clinical evidence in the map pillar and the subjective interpretations in the mood pillar, leading to an overall favorable risk posture for hormonal treatment strategies.”
Proposed action
Continue with the development and dissemination of information regarding hormonal therapies while addressing the misleading narratives around peptide classifications.
THE MECHANICS
What happened
—
THE MACHINE
Sources & records
—
THE MAP
Context & constraints
Estrogen loss during menopause accelerates hearing loss, whereas testosterone increases durability and vitality.
THE MOOD
Framing & reaction
The prior U.S. administration classified certain peptides as dangerous, framing it as a deceptive act towards the incoming administration.